行业观察

Jylo Founders Will Help You Onboard Mike OSS

While some legal tech companies are politely trying to avoid the subject, Jylo’s founders, Sam Lansley and Shawn Curran, are not just embracing the work of vibe-code warriors such as Jamie Tso and Wil

发布时间:2026-05-11来源:Artificial Lawyer
Legal AI’s Next Act Is In-House Productivity

By Daniel Lewis, Global CEO, LegalOn. Law firm AI is constrained by incentives that resist productivity. In-house legal operates in a model designed to reward it. Vast sums are being invested in AI pr

发布时间:2026-05-12来源:Artificial Lawyer
山东乡村旅游:既有乡土味,更有文化魂

本报记者 苏 锐青山环抱的古村传来梆子腔,红柿满枝的山坳迎来八方客,民宿集群里的灯火点亮乡村夜经济……在如今休闲经济得到越来越多消费者认可的背景下,齐鲁大地的乡村旅游正焕发出新生机。近年来,山东省以“有颜值、有内涵、有机制”为抓手,构建起系统完备的政策保障体系,创新“景区带村”“乡村合伙人”“公司+农户”“创客+乡村”等发展模式,走出一条生态优美、文化浸润、群众受益的乡村振兴之路。古村焕发新生机山

发布时间:2026-05-10来源:中国文化报
恒瑞医药与百时美施贵宝达成战略合作协议,携手推进肿瘤学、血液学及免疫学创新疗法

5月12日,恒瑞医药与百时美施贵宝公司宣布双方达成全球战略合作及许可协议,共同推进13款涵盖肿瘤学、血液学及免疫学的早期项目,以加速创新药物研发,惠及全球患者。本次合作协议包含4项恒瑞肿瘤学及血液学项目、4项BMS免疫学项目,以及双方依托恒瑞研发引擎与多元创新技术平台共同研发的5项创新项目。恒瑞拥有共同开发特定项目的选择权,并且有机会与BMS在全球范围内共同开展特定的商业化活动。在本次合作框架下,

发布时间:2026-05-12来源:新华网
Private Space Investment Rebounds Sharply in Q1 2026

Funding surges 145% year over year, driven by fewer but larger deals Paris, France | May 2025 – Novaspace’s newly released Space Innovation Atlas report reveals that private investment in space ventur

发布时间:2026-05-12来源:Space and Satellite Sector Expert | Novaspace
Meet the AI vision Realbotix Vinci robot

AI and humanoid robot manufacturer, Realbotix, has unveiled its first Vinci integrated humanoid robot in partnership with Ericsson, using AI vision that can outperform many humans, with the ability to

发布时间:2026-05-06来源:TechHQ
White House National Economic Council Director says AI isn’t causing job cuts

Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Threads Email Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newslette

发布时间:2026-05-12来源:TechRadar
Why choosing the right software strategy can make or break an SDV

Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Threads Email Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newslette

发布时间:2026-05-12来源:TechRadar
From fragmentation to flow: Rethinking modern software development

Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Threads Email Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newslette

发布时间:2026-05-12来源:TechRadar
Why the chat-AI surge is breaking enterprise tech as we know it

Copy link Facebook X Whatsapp Reddit Pinterest Flipboard Threads Email Share this article 0 Join the conversation Follow us Add us as a preferred source on Google Newsletter Subscribe to our newslette

发布时间:2026-05-12来源:TechRadar
Arizona State University, Rensselaer Polytechnic Institute and Stanford University to join Applied Materials’ EPIC Center in Silicon Valley

News: Suppliers 12 May 2026 Arizona State University, Rensselaer Polytechnic Institute and Stanford University to join Applied Materials’ EPIC Center in Silicon Valley Process equipment maker Applied

发布时间:2026-05-25来源:Semiconductor Today News
Applied Materials and TSMC partner at EPIC Center in Silicon Vallley to accelerate AI scaling

News: Suppliers 12 May 2026 Applied Materials and TSMC partner at EPIC Center in Silicon Vallley to accelerate AI scaling Building on more than 30 years of collaboration, process equipment maker Appli

发布时间:2026-05-25来源:Semiconductor Today News
「AIサーバ、自動車の需要機会を逃さず成長」 太陽誘電の新中計

太陽誘電は2026年5月8日、2026年3月期通期(2025年4月〜2026年3月)の決算を発表した。同期をもって「中期経営計画2025」(2021〜2025年度)が終了したことに伴い、新たな「中期経営計画2030」(2026〜2030年度)を発表した。 太陽誘電26年度は営業利益91.2%増 AIサーバ/車載コンデンサー需要で 経済価値は目標未達も「事業基盤を固められた」 太陽誘電の代表取締役社

发布时间:2026-05-11来源:EETimes Japan
恒瑞和BMS签署152亿美元超级大单

5月12日,恒瑞医药(600276.SH / 01276.HK)与百时美施贵宝(BMS)宣布达成全球战略合作及许可协议,一次性打包13款涵盖肿瘤学、血液学及免疫学的早期项目,潜在总交易额高达约152亿美元,创下中国药企对外授权早期管线规模的新标杆。首付款分3期到账:BMS将向恒瑞支付可达9.5亿美元的近期付款,包括6亿美元首付款、1.75亿美元第一笔周年付款,以及一笔1.75亿美元的有条件2028

发布时间:2026-05-12来源:新药猎人笔记
治疗胆管癌!FDA再批准突破性双抗;FDA批准“first-in-class”疗法扩展适应症

治疗胆管癌!FDA再批准突破性双抗Partner Therapeutics今日宣布,美国FDA已批准Bizengri(zenocutuzumab)用于治疗携带neuregulin 1(NRG1)基因融合、既往接受系统性治疗期间或之后疾病进展的成人晚期、不可切除或转移性胆管癌患者。根据新闻稿,这是首款获批专门针对NRG1阳性胆管癌的靶向疗法。此次批准主要基于eNRGy试验的安全性和有效性数据。eNR

发布时间:2026-05-12来源:药明康德